Document 0748 DOCN M9620748 TI Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. DT 9602 AU Pan ZK; Ikonomidis G; Pardoll D; Paterson Y; Department of Microbiology, University of Pennsylvania,; Philadelphia 19104-6076, USA. SO Cancer Res. 1995 Nov 1;55(21):4776-9. Unique Identifier : AIDSLINE MED/96046570 AB We have shown previously that Listeria monocytogenes, a gram-positive, facultative intracellular bacterium, is a potent vector for targeting tumor-specific antigens to the immune system. After parenteral administration, we observed protection against both renal and colorectal mouse tumors and regression of established renal tumors. In the present study, we have exploited the fact that the normal route of infection of this organism is through the gut. We show that an L. monocytogenes recombinant that expresses a model tumor antigen is an effective cancer immunotherapeutic agent when delivered orally in that it causes regression of established, macroscopic mouse renal and colorectal tumors expressing the same antigen. DE Administration, Oral Animal Antigens, Neoplasm/IMMUNOLOGY Antigens, Viral/GENETICS/IMMUNOLOGY Bacterial Vaccines/*THERAPEUTIC USE Carcinoma, Renal Cell/IMMUNOLOGY/THERAPY Colonic Neoplasms/IMMUNOLOGY/THERAPY Gene Products, gag/METABOLISM Immunotherapy, Active Kidney Neoplasms/IMMUNOLOGY/THERAPY Listeria monocytogenes/GENETICS/*IMMUNOLOGY Melanoma, Experimental/THERAPY Mice Mice, Inbred BALB C Mice, Inbred C57BL Neoplasms, Experimental/IMMUNOLOGY/*THERAPY Nucleoproteins/IMMUNOLOGY Recombinant Proteins/GENETICS/IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes, Cytotoxic/IMMUNOLOGY Transduction, Genetic Tumor Cells, Cultured Vaccines, Synthetic/*THERAPEUTIC USE Viral Core Proteins/IMMUNOLOGY JOURNAL ARTICLE SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).